CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06885697
Title field or adapter rule: {'original_value': 'Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:23.204857+00:00
Published At: 2026-10-16T00:00:00+00:00
Record Updated At: 2026-10-16
Source Retrieved At: 2026-10-31T22:17:52.415050+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Mesothelioma", "Neoplasms", "Stomach Neoplasms", "Pancreatic Neoplasms", "Ovarian Neoplasms", "Lung Neoplasms", "Thymus Neoplasms", "Colonic Neoplasms"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-16", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06885697"
protocolSection.identificationModule.officialTitle: "Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['1/Dose Escalation', '2/Dose Expansion'], 'description': '600 mg/m\\^2 IV infusion. Daily x 3 doses on Day -6, -5, -4', 'name': 'cyclophosphamide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/Dose Escalation', '2/Dose Expansion'], 'description': '30 mg/m\\^2 IV infusion administered followed by cyclophosphamide on days both are given. Daily x 4 doses on Day -7, -6, -5 and -4', 'name': 'fludarabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/Dose Escalation', '2/Dose Expansion'], 'description': 'Variable doses, administered intravenously on Day 0', 'name': 'TNhYP218 CAR T Cells', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/Dose Escalation', '2/Dose Expansion'], 'description': 'Assay done at screening to determine mesothelin expression levels', 'name': 'mesothelin expression testing', 'type': 'DEVICE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.